key: cord-0822137-xn2w20nn
authors: Deckers, Eric A.; Kruijff, Schelto; Bastiaannet, Esther; van Ginkel, Robert J.; Hoekstra‐Weebers, Josette E. H. M.; Hoekstra, Harald J.
title: Obesity is not associated with disease‐free interval, melanoma‐specific survival, or overall survival in patients with clinical stage IB‐II melanoma after SLNB
date: 2021-06-04
journal: J Surg Oncol
DOI: 10.1002/jso.26555
sha: 89ac2153081acc37868b9a85dfb9f976bd35b020
doc_id: 822137
cord_uid: xn2w20nn

BACKGROUND AND OBJECTIVES: Clinicopathologic characteristics have prognostic value in clinical stage IB‐II patients with melanoma. Little is known about the prognostic value of obesity that has been associated with an increased risk for several cancer types and worsened prognosis after diagnosis. This study aims to examine effects of obesity on outcome in patients with clinical stage IB‐II melanoma. METHODS: Prospectively recorded data of patients with clinical stage IB‐II melanoma who underwent sentinel lymph node biopsy (SLNB) between 1995 and 2018 at the University Medical Center of Groningen were collected from medical files and retrospectively analyzed. Cox‐regression analyses were used to determine associations between obesity (body mass index> 30), tumor (location, histology, Breslow‐thickness, ulceration, mitotic rate, SLN‐status) and patient‐related variables (gender, age, and social‐economic‐status [SES]) and disease‐free interval (DFI), melanoma‐specific survival (MSS), and overall survival (OS). RESULTS: Of the 715 patients, 355 (49.7%) were women, median age was 55 (range 18.6‐89) years, 149 (20.8%) were obese. Obesity did not significantly affect DFI (adjusted hazard ratio [HR] = 1.40; 95% confidence interval [CI] = 0.98–2.00; p = 0.06), MSS (adjusted HR = 1.48;95%CI = 0.97–2.25; p = 0.07), and OS (adjusted HR = 1.25; 95% CI = 0.85–1.85; p = 0.25). Increased age, arm location, increased Breslow‐thickness, ulceration, increased mitotic rate, and positive SLN‐status were significantly associated with decreased DFI, MSS, and OS. Histology, sex, and SES were not associated. CONCLUSION: Obesity was not associated with DFI, MSS, or OS in patients with clinical stage IB‐II melanoma who underwent SLNB.

In the Netherlands, the annual incidence of melanoma doubled from 3604 to 7127 new cases between 2005 and 2019. Notably, the incidence specifically increased among people ≥45 years of age, while remaining stable among individuals of less than 45 years old. 1 The rising melanoma incidence is mainly attributed to the increased ageing of our population; ozone layer depletion that has amplified the intensity of ultraviolet radiation; and lifestyle changes, such as sun-seeking behavior and tanning bed use. 2, 3 There have also been changes in the distribution and stage of melanoma at diagnosis, with a higher percentage of thin melanomas diagnosed, further increasing the prevalence of melanoma diagnosis. 1, 4 Among patients with clinical stage IB-II melanoma, prognosis is based on and well-defined for several tumor and clinicopathologic factors, including primary tumor site; Breslow thickness; mitotic rate, ulceration; regression; histopathologic subtype; sentinel lymph node status; and patient characteristics, such as age and sex. [5] [6] [7] [8] [9] For patients with localized melanoma, the most important predictor of outcome is the presence of regional lymph node metastases. 9 Modern lifestyle changes have led to significantly increased obesity rates. Obesity develops gradually and is commonly associated with high-fat and high-sugar diets, and a physically inactive lifestyle. The prevalence of obesity has doubled since 1980. 10 Worldwide in 2016, among adults over 18 years of age, 39% were overweight, and 13% were obese. 11 In 2018 in the Netherlands, 50% percent of adults were overweight and 15% were obese. 12 Obesity constitutes a serious public health problem, potentially increasing the risks of many health issues, including diabetes, cardiovascular disease, and musculoskeletal disorders. Obesity is an established endogenous risk and progression factor associated with significantly higher all-cause mortality, 11 and is an important risk factor for the development of various types of cancer-specifically breast, ovary, colorectal, uterine corpus, esophagus (adenocarcinoma), pancreatic, kidney (renal cell), liver, stomach (gastric cardia), gallbladder, thyroid, multiple myeloma, and brain (meningioma) cancers. 13 In the USA, 5% of all new cancers in men and 11% in women are attributable to obesity. 14 While obesity is clearly a risk factor for the development of various cancers, its effects on survival seem to be more complex. According to the obesity paradox, although obesity is associated with an increased risk of cancer compared to normal weight, once cancer is diagnosed, patients with cancer and with a moderately increased body mass index (BMI) exhibit improved outcomes compared to those of normal weight, while patients with morbid obesity and cancer have worse outcomes. 15 The association between obesity and melanoma risk and outcome remains unclear. 16 A meta-analysis identified an elevated melanoma risk with increasing BMI among men, whereas a pooled case-control study among women demonstrated a null association between BMI and melanoma risk. 17, 18 Discrepant results have also been reported regarding outcomes, for example, disease progression and survival. Some studies have found associations between elevated BMI and worse melanoma outcome, 19 while others report no association between BMI and melanoma survival. 20 Additionally, one study found improved outcomes in male obese patients with metastatic melanoma who were treated with immune or targeted therapy, but no significant associations between obesity and outcomes among women or in patients receiving chemotherapy. 21 Obesity is more prevalent among people with lower socioeconomic status (SES) compared to those with higher SES. 22 Moreover, obesity reportedly shows a negative association with SES among patients with melanoma. 23 Additionally, among patients with melanoma, those with a lower SES (measured as lower median household income) more commonly presented with advanced stages of melanoma and exhibited shorter survival. 24, 25 In the current study, we aimed to investigate the impact of obesity at diagnosis on disease-free interval (DFI), melanoma-specific All patients were offered SLNB as standard procedure, with no exclusion criteria. Informed consent was required. The same SLNB procedure was used for all patients, including lymphoscintigraphy with 99 mTc nanocolloid and blue dye technique, with an identification rate of 99%, as previously described. 26 No changes were made to the lymphoscintigraphy technique (e.g., SPECT/CT) during the study time period.

The institutional guidelines applicable during the study per- 

Statistical analyses were performed using STATA/SE 12.0. Patient characteristics were described, and obese and nonobese patients were compared using χ 2 tests for categorical variables, and a nonparametric test for the equality of medians for age. Cox proportionalhazards models were used to examine associations of clinicopathologic and patient characteristics with DFI, MSS, and OS. We calculated the five-year rates of DFI, MSS, and OS, and assessed the univariable and multivariable hazard ratios (HR) with corresponding 95% confidence intervals (CIs) for the entire follow-up period. DFI was defined as the time from wide excision until recurrence or death due to melanoma, MSS as the time from wide excision until death Figure 1A -C).

The other analyzed variables were significantly associated with DFI, MSS, and OS (Tables 2-4 Our present results are in line with the findings of an earlier study that showed no association between high BMI and melanoma mortality, 20 but in contrast with a report that elevated BMI was associated with worse outcomes in patients with melanoma, after adjustment for sex, age, and stage. 19 Our present findings are also in contrast to a report showing improved outcomes in obese male patients with metastatic melanoma who received targeted therapy or immunotherapy. 21 Moreover, the current findings do not support the obesity paradox-a phenomenon that has previously been criticized. The contradictory reports regarding the existence of an obesity paradox may be explained by methodological issues (e.g., BMI being a suboptimal measure; confounding, selection, and detection biases; and reverse causality) and/or clinical issues (e.g., tumor aggressiveness and treatment responses). 15 Obesity induces immune suppression via inflammation, and accelerates tumor growth. 28 When melanoma invades deeper layers of the skin, papillary, reticular dermis, or the subcutis, the melanoma cells reportedly interact with adipose tissue, which secretes both soluble factors and exosomes, thus supporting melanoma proliferation, invasiveness, and metastatic potential, 29, 30 This may explain the finding that ulceration was more common in patients with obesity compared to nonobese patients. The effects of obesity on melanoma growth patterns, and on immune responses both in general and in cancer immunotherapy, are poorly understood. 16 A recent study documented a positive correlation between overweight status and the efficacy of immune checkpoint inhibitors in metastatic melanoma and other malignancies. 30 Experiments in a melanoma mouse model showed that obesity promotes tumor progression and immune dysfunction, particularly through PD-1 upregulation. 28 This could be an explanation for the improved response to PD-1/PD-L1 inhibition treatment, rather than the previously proposed obesity paradox. 15 There are a number of potential explanations for the present findings. Compared to most other malignancies, melanoma is generally diagnosed at an earlier age and lower stage, 32 and the tumor biology and host immunity differ among patients with melanoma at different ages. 33 The treatment of clinical stage IB-II melanoma comprises surgical (re-) excision of the tumor and SLNB under local, regional, or general anesthesia. 8 Therefore, the only factors that may affect the immune system are gender and age. 34 In accordance with the literature, our present study showed that age was an independent predictor of melanoma progression, MSS, and OS.

Also in accordance with the literature, male patients with melanoma were found to have worse outcomes compared to female patients in univariate analyses. 35, 36 However, in multivariate analyses, these differences were no longer significant, indicating that other variables included in the analyses played a greater role than gender in determining disease progression and survival.

In the Netherlands, people with lower SES are more commonly overweight and obese. 37 The Dutch Cancer Registry showed that low SES was associated with advanced melanoma. 38 However, our present study found that SES was not associated with DFI, MSS, or OS among clinical stage IB-II melanoma patients who underwent SLNB. It is reassuring to find that SES does not influence these disease outcomes T A B L E 3 Melanoma-specific survival (MSS) (univariable and multivariable analyses) according to patient and tumor characteristics The percentage of obese (BMI ≥ 30 kg/m 2 ) patients found in the current study (20.8%) is higher than the rate found in the general population in the Netherlands in 2018 (15%). 40 However, the latter percentage is based on self-report, while the BMI in the present study was objectively measured using recorded body height and weight from the time of diagnosis.

A strength of the current study is that it included a large cohort with prospectively collected baseline data on several potential confounders in the relationships between BMI and DFI, MSS, and OS. Additionally, BMI was calculated using objectively measured body weight and height at the time of primary diagnosis. Questionnaire-based self-report is more prone to error.

A limitation of this study is that obesity was determined using only BMI, and not measures like fat mass and fat-free mass index, which may be more sensitive. 41 A second limitation is that we could not examine how changes in adiposity levels before and after diagnosis may have influenced oncological endpoints. It has been shown that changes in adiposity levels affect disease and outcomes in several types of malignancies. 42 would have been a larger study group, likely including a greater number of patients with obesity. A fourth limitation is that the metastatic tumor burden in the sentinel lymph node was not systematically recorded in the patients' files during the study period. It may be possible that the lymph node metastases, on average, were larger among patients with obesity.

However, we were unable to control for this variable.

In our present analyses, we adjusted for a number of clinicopathological and patient characteristics known to affect melanoma progression and survival. Other variables have also been reported to be associated with cancer outcomes, including biomarkers (LDH, S-100B), tumor immune response-related cytokines/chemokines, inflammatory markers (C-reactive protein), and smoking behavior. 19, [45] [46] [47] [48] A relationship has been identified between smoking and SLN metastasis in stage IB-II melanoma, which is independent of tumor thickness and ulceration. 46 Additionally, links have been described between obesity, inflammation, and immune response, and the impacts on the metastatic potential of malignancies and on disease outcome. [19] [20] [21] 49 The linkage between immune response and obesity has also been identified in coronavirus diaease 2019 infection, as obesity is a risk factor for higher severity and worse prognosis. 50, 51 Unfortunately, in the present study, we were unable to investigate relationships between all of these variables, and obesity and disease outcome. Future studies should include such variables in analyses.

The present study showed that obesity (BMI ≥ 30 kg/m 2 ) was not significantly associated with DFI, MSS, or OS in patients with clinical stage IB-II melanoma who underwent SLNB. Among these patients, increased age was associated with decreased DFI, MSS, and OS. Outcomes were not significantly associated with gender or SES in our cohort. Compared to their counterparts, patients with melanoma on the arm, thicker melanoma, ulceration, a mitotic rate of ≥5/mm 2 , and/or a positive sentinel lymph node status exhibited decreased DFI, MSS, and OS.

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. 

Stratospheric ozone depletion, ultraviolet radiation and health. Climate Change and Human Health-Risks and Responses. WHO

Cancer statistics, 2020

Long-term follow-up reveals that ulceration and sentinel lymph node status are the strongest predictors for survival in patients with primary cutaneous melanoma

Tumor mitotic rate added to the equation: melanoma prognostic factors changed? A single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients

Prognostic factors analysis of 17,600 melanoma patients: validation of the American joint committee on cancer melanoma staging system

Melanoma staging: evidence-based changes in the american joint committee on cancer eighth edition cancer staging manual

Completion dissection or observation for sentinel-node metastasis in melanoma

Health effects of overweight and obesity in 195 countries over 25 Years

Rijksinstituut voor volkgezondheid en milieu. The Netherlands

International agency for research on cancer handbook working group. body fatness and cancer--viewpoint of the IARC working group

Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States

The obesity paradox in cancer: a review

Obesity and the impact on cutaneous melanoma: Friend or foe? Cancers

Obesity and risk of malignant melanoma: a meta-analysis of cohort and case-control studies

Anthropometric factors and risk of melanoma in women: a pooled analysis

Association between body mass index, Creactive protein levels, and melanoma patient outcomes

Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

Income and obesity: what is the direction of the relationship? A systematic review and metaanalysis

Socioeconomic and lifestyle factors and melanoma: a systematic review

Impact of socioeconomic status and ethnicity on melanoma presentation and recurrence in caucasian patients

Socioeconomic status and survival for patients with melanoma in the United States: an NCDB analysis

Is sentinel node biopsy beneficial in melanoma patients? A report on 200 patients with cutaneous melanoma

The Netherlands Institute for Social Research (SCP)

Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade

Obesity and melanoma: could fat be fueling malignancy?

The surprisingly positive association between obesity and cancer immunotherapy efficacy

Complex interrelationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition

Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) program

Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts

Causes, consequences, and reversal of immune system aging

Survival of cutaneous melanoma based on sex, age, and stage in the United States

Gender differences in melanoma survival: female patients have a decreased risk of metastasis

Cross-National Comparisons of Socioeconomic Differences in Overweight and Obesity

Sociodemographic factors and incidence of melanoma in the Netherlands

Increase of sentinel lymph node melanoma staging in The Netherlands; still room and need for improvement

Volksgezondheid en zorg. The Netherlands

The role of fat mass index in determining obesity

Swedish women

BMI and weight changes and risk of obesity-related cancers: a pooled European cohort study

Body mass index (BMI), BMI change, and overall survival in patients with SCLC and NSCLC: a pooled analysis of the International Lung Cancer Consortium

The predictive power of serum S-100B for non-sentinel node positivity in melanoma patients

The impact of smoking on sentinel node metastasis of primary cutaneous melanoma

Role of immune response, inflammation, and tumor immune responserelated cytokines/chemokines in melanoma progression

Role of obesity in smoking behaviour: mendelian randomisation study in UK Biobank

Obesity and outcomes in COVID-19: when an epidemic and pandemic collide

Obesity as a predictor for a poor prognosis of COVID-19: a systematic review

Obesity is not associated with disease-free interval, melanoma-specific survival, or overall survival in patients with clinical stage IB-II melanoma after SLNB

http://orcid.org/0000-0001-6206-207X